瘤微环境的活性氧物种:利用免疫性细胞死亡
RamaRao Malla1, Seema Kumari1, Swapna Priya Ganji1
1Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, School of Science, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India.
Biochimica et biophysica acta. Reviews on cancer
|July 17, 2024
概括
改变的瘤微环境限制了癌症免疫疗法. 这篇评论强调了活性氧物种 (ROS) 如何诱导免疫细胞死亡 (ICD),将冷瘤转化为热瘤,以获得更好的免疫反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 瘤微环境 (TME) 是一个复杂的系统,影响瘤进展并影响癌症免疫疗法的疗效.
- 在TME内改变的氧化还原稳定常常导致瘤免疫性不足,限制治疗的成功.
- 传统和向疗法可以通过诱导免疫细胞死亡 (ICD) 来增强免疫疗法.
研究的目的:
- 审查氧化还原平衡在调节TME从"冷"到"热"表型中的作用.
- 阐明反应性氧物种 (ROS) -ICD轴在启动抗瘤免疫反应中的作用.
- 探索利用ROS生成的策略,在较少免疫性瘤中进行有效的癌症免疫疗法.
主要方法:
- 文献综述侧重于减氧稳态,TME动态和免疫细胞死亡.
- 对连接ROS产生,DAMP释放和免疫细胞激活的机制的分析.
- 综合当前利用ROS诱导ICD的治疗策略.
主要成果:
- 氧化还原稳定极大地影响了TME表型和免疫细胞透.
- 依赖ROS的ICD触发了损伤相关分子模式 (DAMP) 的释放.
- DAMP激活免疫细胞上的模式识别受体 (PRR),促进抗瘤免疫力.
结论:
- 操纵氧化还原稳定是克服TME相关免疫疗法耐药性的关键.
- ROS-ICD途径提供了一种有前途的策略,可以在具有挑战性的瘤中增强免疫性.
- 开发基于ROS的免疫疗法有可能治疗免疫性较低的固体瘤.
相关概念视频
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cytotoxic T Cells-mediated Immune Response
885
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
885
Electron Transport Chain: Complex I and II
12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


